Organisation paid for research Program year 2025 Source: CMS Open Payments

Rhode Island Hospital

Neither a doctor nor a teaching hospital

Research payments

$3,726,922

145 payments

Through program year 2025, Rhode Island Hospital is reported as receiving $3,726,922 in research payments, across 145 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $646,934 24
2024 Research $1,310,159 19
2023 Research $194,875 11
2022 Research $809,763 46
2021 Research $163,134 13
2020 Research $243,257 19
2019 Research $358,800 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,275,531 12 payments
  2. Eisai Inc. $327,871 13 payments
  3. E.R. Squibb & Sons, L.L.C. $318,284 1 payment
  4. Moderna TX, Inc. $298,000 31 payments
  5. Novartis Pharmaceuticals Corporation $270,714 6 payments
  6. Genmab U.S., Inc. $205,316 16 payments
  7. Sun Pharmaceutical Industries Inc. $168,123 6 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $127,975 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $114,450 3 payments
  10. Sanofi Pasteur Inc. $108,020 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III or FC IV at High Risk of Mortality $615,722 3 payments
  2. A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF $504,887 3 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $327,871 13 payments
  4. A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy $318,284 1 payment
  5. A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS CoV 2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls $298,000 31 payments
  6. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $211,800 2 payments
  7. A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. $205,316 16 payments
  8. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $153,954 4 payments
  9. Combo with PD-1 inhibitor $127,975 3 payments
  10. X16117: Phase I/II Study of Twice-Weekly Ixazomib in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma $114,450 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $19,468 2 payments
  2. Non-patient care $2,860 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record